Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 4/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9317096 | 0.89 | LDHA (0.52) | ACACBLDHAEPHX1ESR1ESR2 | |
| SCHEMBL2426124 | 0.84 | MMP8 (0.54) | ACACBMMELDHAMEN1KMT2A | |
| SCHEMBL12459110 | 0.83 | MME (0.53) | ACACBMMEMEN1NPC1RAB9A | |
| SCHEMBL18921686 | 0.83 | MME (0.45) | ACACBMMEPPARGPPARALDHA | |
| SCHEMBL27205 | 0.83 | LDHA (0.57) | MMEPPARGPPARALDHA | |
| SCHEMBL2576380 | 0.82 | MME (0.43) | ACACBMMELDHAEPHX1ESR1 | |
| SCHEMBL19369764 | 0.82 | ACACB (0.47) | ACACBMMEPPARGPPARAEPHX1 | |
| SCHEMBL22235331 | 0.82 | KMT2A (0.53) | ACACBMMEEPHX1ESR1ESR2 | |
| SCHEMBL3634087 | 0.82 | ACACB (0.47) | ACACBMMEPPARGPPARAEPHX1 | |
| SCHEMBL14355742 | 0.82 | SLC7A5 (0.48) | ACACBMMEEPHX1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020142228-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-07-09 | — | — | WO | disclosed |
| US-9382253-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2016-07-05 | — | — | US | disclosed |
| CN-102985433-B | Metal complex | 默克专利有限公司 | 2016-06-15 | — | — | CN | disclosed |
| US-20130112921-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2013-05-09 | — | — | US | disclosed |
| US-7935847-B2 | Nitroxyl ion source with second order reaction nitroxyl release | DUKE UNIVERSITY (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935847-B2 | Nitroxyl ion source with second order reaction nitroxyl release | DUKE UNIVERSITY (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935847-B2 | Nitroxyl ion source with second order reaction nitroxyl release | DUKE UNIVERSITY (US) | 2011-05-03 | — | — | US | disclosed |
| US-20100094060-A1 | NITROXYL ION SOURCE WITH SECOND ORDER REACTION NITROXYL RELEASE | DUKE UNIVERSITY (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100094060-A1 | NITROXYL ION SOURCE WITH SECOND ORDER REACTION NITROXYL RELEASE | DUKE UNIVERSITY (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100094060-A1 | NITROXYL ION SOURCE WITH SECOND ORDER REACTION NITROXYL RELEASE | DUKE UNIVERSITY (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2008130566-A1 | NITROXYL ION SOURCE WITH SECOND ORDER REACTION NITROXYL RELEASE | DUKE UNIVERSITY (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130566-A1 | NITROXYL ION SOURCE WITH SECOND ORDER REACTION NITROXYL RELEASE | DUKE UNIVERSITY (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094060-A1 | NITROXYL ION SOURCE WITH SECOND ORDER REACTION NITROXYL RELEASE | NOS2, NOS1, NOS3 | ACACB 3829/4885MME 900/4885PPARG 4632/4885 |
| US-20130112921-A1 | METAL COMPLEXES | MCOLN2, MCOLN1, NCLN | ACACB 3706/4885MME 810/4885PPARG 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.